Proteostasis Therapeutics, Inc., a biopharmaceutical company, announced the appointment of James M. DeTore as chief financial officer.
Proteostasis Therapeutics announces appointmentsStaff Writer | Cambridge, Mass., USA | Tuesday August 9, 2016 8:09AM ET
READ MOREMr. DeTore joins the company from bluebird bio, Inc., where he served as chief financial officer from 2014 through 2016.
Prior to bluebird, he served for eight years in positions of increasing responsibility at Ironwood Pharmaceuticals, Inc., culminating as vice president of corporate finance and prior to that as the corporate controller at Ironwood’s predecessor company, Microbia, Inc.
Mr. DeTore received his Master of Business Administration and bachelor’s degree in finance from Northeastern University.
The company appoints Geoffrey S. Gilmartin as chief development officer.
Dr. Gilmartin joins Proteostasis Therapeutics from AstraZeneca, where he most recently served as senior medical lead for global medicines development, including the company’s benralizumab Phase 3 program in severe asthma. Dr. Gilmartin joined AstraZeneca in January 2014.
Prior to his time there, he held positions of increasing responsibility at Vertex Pharmaceuticals including serving as medical lead for the KalydecoTM (ivacaftor) clinical development program, as well as spearheading the initiation of Phase 3 trials to support label expansion studies for the drug.
Dr. Gilmartin joined Vertex Pharmaceuticals in January 2011. In addition to his leadership in the life sciences industry, Dr. Gilmartin is an attending physician for the intensive care unit at Beth Israel Deaconess Medical Center and formerly served as director of the BIDMC Sleep Disorders Center and on the pulmonary leadership team.
Dr. Gilmartin completed his undergraduate degree atDartmouth College and received his M.D. from Brown University School of Medicine and his Master of Medical Science in clinical research from Harvard Medical School.
The company also appoints Marija Zecevic as vice president of business development.
Dr. Zecevic has collaborated with Proteostasis Therapeutics on multiple projects since July 2014. Dr. Zecevic was the founder and managing director at Zebra Ventures, a consulting firm based inItaly where she led licensing discussions with top 10 pharma companies on behalf of the firm’s clients among which was the Italian Cystic Fibrosis Research Foundation.
Prior to that, Dr. Zecevic held several positions of increasing responsibility at Bioxell, a Roche spin-off where she supported all licensing and fundraising activities from top tier European and U.S. venture capital firms that culminated in an IPO on the Swiss Stock Exchange in 2006.
Dr. Zecevic received her Ph.D. in physiology from the University of Zurich and a Master of Science in healthcare management, economics and policy from the University Bocconi in Milan.
In addition to the appointments of Mr. DeTore, Dr. Gilmartin and Dr. Zecevic, Proteostasis Therapeutics has appointed Eric B. Rabinowitz to its board of directors.
Mr. Rabinowitz joins Proteostasis Therapeutics from Perrigo Company, PLCwhere he is the vice president of global corporate development and leads the team in devising Perrigo’s strategy and identifying and executing inorganic growth opportunities to achieve its long-term objectives.
Prior to joining Perrigo in August 2014, Mr. Rabinowitz held several positions of increasing responsibility over an 11 year career in investment banking.
Mr. Rabinowitz earned his undergraduate degree from the University of Florida, Fischer School of Accounting and a Master of Business Administration from The University of Chicago Booth School of Business.
Conor Walshe will be stepping down. ■
Valeant Q2 revenues decreased 11%
Valeant Q2 revenues decreased 11%